EA201201476A1 - Синтез кето-эпоксидов аминокислот - Google Patents

Синтез кето-эпоксидов аминокислот

Info

Publication number
EA201201476A1
EA201201476A1 EA201201476A EA201201476A EA201201476A1 EA 201201476 A1 EA201201476 A1 EA 201201476A1 EA 201201476 A EA201201476 A EA 201201476A EA 201201476 A EA201201476 A EA 201201476A EA 201201476 A1 EA201201476 A1 EA 201201476A1
Authority
EA
Eurasian Patent Office
Prior art keywords
epoxides
keto
amino acids
synthesis
specifically
Prior art date
Application number
EA201201476A
Other languages
English (en)
Other versions
EA024437B1 (ru
Inventor
Пасит Пхиасивонгса
Луис С. Сехл
Уилльям Дин Фуллер
Гай Дж. Лэйдиг
Original Assignee
Оникс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39941499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201476(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Оникс Терапьютикс, Инк. filed Critical Оникс Терапьютикс, Инк.
Publication of EA201201476A1 publication Critical patent/EA201201476A1/ru
Publication of EA024437B1 publication Critical patent/EA024437B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62C—FIRE-FIGHTING
    • A62C3/00—Fire prevention, containment or extinguishing specially adapted for particular objects or places
    • A62C3/002—Fire prevention, containment or extinguishing specially adapted for particular objects or places for warehouses, storage areas or other installations for storing goods
    • A62C3/004—Fire prevention, containment or extinguishing specially adapted for particular objects or places for warehouses, storage areas or other installations for storing goods for freezing warehouses and storages
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62C—FIRE-FIGHTING
    • A62C35/00—Permanently-installed equipment
    • A62C35/58—Pipe-line systems
    • A62C35/68—Details, e.g. of pipes or valve systems
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62C—FIRE-FIGHTING
    • A62C37/00—Control of fire-fighting equipment
    • A62C37/08—Control of fire-fighting equipment comprising an outlet device containing a sensor, or itself being the sensor, i.e. self-contained sprinklers
    • A62C37/10—Releasing means, e.g. electrically released
    • A62C37/11—Releasing means, e.g. electrically released heat-sensitive
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D301/00—Preparation of oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D301/00—Preparation of oxiranes
    • C07D301/02—Synthesis of the oxirane ring
    • C07D301/03—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62C—FIRE-FIGHTING
    • A62C35/00—Permanently-installed equipment
    • A62C35/58—Pipe-line systems
    • A62C35/60—Pipe-line systems wet, i.e. containing extinguishing material even when not in use
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62C—FIRE-FIGHTING
    • A62C35/00—Permanently-installed equipment
    • A62C35/58—Pipe-line systems
    • A62C35/62—Pipe-line systems dry, i.e. empty of extinguishing material when not in use
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62C—FIRE-FIGHTING
    • A62C37/00—Control of fire-fighting equipment
    • A62C37/08—Control of fire-fighting equipment comprising an outlet device containing a sensor, or itself being the sensor, i.e. self-contained sprinklers
    • A62C37/10—Releasing means, e.g. electrically released
    • A62C37/11—Releasing means, e.g. electrically released heat-sensitive
    • A62C37/14—Releasing means, e.g. electrically released heat-sensitive with frangible vessels

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Business, Economics & Management (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Operations Research (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

Настоящее изобретение относится к способу получения кето-эпоксидов аминокислот. Конкретно, аллильные кетоны стереоселективно преобразуют до желаемых кето-эпоксидов аминокислот.
EA201201476A 2007-10-04 2008-10-03 Синтез кето-эпоксидов аминокислот EA024437B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99761307P 2007-10-04 2007-10-04
US898707P 2007-12-20 2007-12-20

Publications (2)

Publication Number Publication Date
EA201201476A1 true EA201201476A1 (ru) 2013-07-30
EA024437B1 EA024437B1 (ru) 2016-09-30

Family

ID=39941499

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201201476A EA024437B1 (ru) 2007-10-04 2008-10-03 Синтез кето-эпоксидов аминокислот
EA201070429A EA018973B1 (ru) 2007-10-04 2008-10-03 Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201070429A EA018973B1 (ru) 2007-10-04 2008-10-03 Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот

Country Status (36)

Country Link
US (3) US8367617B2 (ru)
EP (3) EP2612856B8 (ru)
JP (2) JP5734656B2 (ru)
KR (5) KR20170040374A (ru)
CN (1) CN101883779B (ru)
AR (1) AR068681A1 (ru)
AU (1) AU2008307510A1 (ru)
CA (1) CA2701778C (ru)
CL (2) CL2008002966A1 (ru)
CO (1) CO6270366A2 (ru)
CR (1) CR11364A (ru)
CY (1) CY1117710T1 (ru)
DK (1) DK2207791T4 (ru)
DO (1) DOP2010000095A (ru)
EA (2) EA024437B1 (ru)
EC (1) ECSP10010103A (ru)
ES (2) ES2684340T3 (ru)
HK (1) HK1149573A1 (ru)
HR (1) HRP20160808T4 (ru)
HU (1) HUE029665T2 (ru)
IL (5) IL204890A0 (ru)
MA (1) MA31831B1 (ru)
ME (1) ME02462B (ru)
MX (1) MX2010003732A (ru)
MY (2) MY173938A (ru)
NZ (2) NZ584814A (ru)
PH (1) PH12013501377A1 (ru)
PL (1) PL2207791T5 (ru)
PT (1) PT2207791T (ru)
RS (1) RS54847B2 (ru)
SA (1) SA08290624B1 (ru)
SG (2) SG10201902704TA (ru)
SI (1) SI2207791T2 (ru)
TW (1) TWI501773B (ru)
WO (1) WO2009045497A1 (ru)
ZA (1) ZA201002770B (ru)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
AU2005238445B2 (en) 2004-04-15 2012-05-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
ES2510840T3 (es) 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
PL2623113T3 (pl) 2005-11-09 2018-05-30 Onyx Therapeutics, Inc. Związek do hamowania enzymu
EP2484688B1 (en) 2006-06-19 2016-06-08 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
US8367617B2 (en) 2007-10-04 2013-02-05 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
JP6042724B2 (ja) 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
EP2555621A4 (en) * 2010-04-07 2014-07-02 Onyx Therapeutics Inc CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
AU2013226073B2 (en) * 2012-02-28 2016-05-05 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
KR20190137963A (ko) * 2012-05-08 2019-12-11 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
AU2012238318B2 (en) * 2012-05-08 2014-02-13 Onyx Therapeutics, Inc. Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
US9187442B2 (en) 2012-06-29 2015-11-17 Nissan Chemical Industies, Ltd. Method for producing stereoselective epoxyketone compound
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
CN109096370B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
WO2014018807A1 (en) * 2012-07-26 2014-01-30 Centrax International, Inc. Peptide epoxyketone compounds
US9636376B2 (en) * 2012-09-11 2017-05-02 Innopharma, Inc. Stable compositions of peptide epoxy ketones
CA2888822C (en) 2012-10-22 2021-01-26 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
UY35091A (es) * 2012-10-24 2014-05-30 Onyx Therapeutics Inc Formulaciones de liberacion modificada para oprozomib
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
US9795638B1 (en) * 2013-03-16 2017-10-24 BioDlogics, LLC Cardiothoracic construct and methods of use
AU2014290012B2 (en) 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CA2920220A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Synthesis of peptide epoxy ketones
CN105517998A (zh) * 2013-09-06 2016-04-20 桑多斯股份公司 通过曼尼希反应立体选择性合成二醇和三醇以及它们在卡非佐米合成中的用途
WO2015121769A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
CN104230857A (zh) * 2014-08-19 2014-12-24 上海皓元生物医药科技有限公司 卡非佐米(Carfilzomib)的中间体化合物的制备方法及其中间体化合物
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
WO2016046843A1 (en) 2014-09-24 2016-03-31 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
US20160115198A1 (en) 2014-10-27 2016-04-28 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
ES2742196T3 (es) 2014-12-02 2020-02-13 Fresenius Kabi Oncology Ltd Un procedimiento para la purificación de carfilzomib
US10301353B2 (en) 2014-12-31 2019-05-28 Dr. Reddy's Laboratories Limited Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
CN105985408B (zh) * 2015-02-12 2020-06-26 正大天晴药业集团股份有限公司 一种卡非佐米的纯化方法
CN104844540A (zh) * 2015-05-18 2015-08-19 上海凯欣生物医药科技有限公司 一种(2s)-2-氨基-4-甲基-1-[(2r)-2-甲基环氧乙烷基]-1-戊酮三氟乙酸盐的新晶型及其制备方法
EP3297678B1 (en) 2015-05-21 2021-07-07 Laurus Labs Limited An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
CN104961799B (zh) * 2015-06-19 2021-05-11 重庆医药工业研究院有限责任公司 一种卡非佐米晶型a及其制备方法
CN105017181B (zh) * 2015-07-02 2017-10-10 南京师范大学 卡非佐米关键中间体及其衍生物的制备方法
CN105294501B (zh) * 2015-08-21 2017-09-29 上海应用技术学院 一种卡非佐米中间体化合物的制备方法
US20180362580A1 (en) 2015-12-11 2018-12-20 Mylan Laboratories Limited Crystalline and amorphous forms of carfilzomib
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
WO2018005781A1 (en) 2016-06-29 2018-01-04 Kezar Life Sciences Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
KR102655020B1 (ko) 2016-06-29 2024-04-04 케자르 라이프 사이언스 펩티드 에폭시케톤 면역프로테아좀 억제제의 결정질 염
EP3494126A1 (en) 2016-08-02 2019-06-12 Synthon BV Process for making carfilzomib
CR20190113A (es) 2016-08-05 2019-04-25 Amgen Inc Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma
EP3330260A1 (en) 2016-12-01 2018-06-06 Enantia, S.L. Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
CA3082786A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Stable compositions of pegylated carfilzomib compounds
CN113200943A (zh) * 2021-04-23 2021-08-03 湖南华腾制药有限公司 一种卡非佐米中间体的制备方法
CN114195741A (zh) * 2021-12-28 2022-03-18 南京格亚医药科技有限公司 一种卡非佐米关键中间体异构体的制备方法
CN116023347A (zh) * 2022-10-09 2023-04-28 无锡紫杉药业股份有限公司 一种卡非佐米侧链的异构体制备方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5071957A (en) * 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US4990448A (en) * 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
AU661270B2 (en) 1990-03-05 1995-07-20 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en) 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
TW380137B (en) * 1994-03-04 2000-01-21 Merck & Co Inc Process for making an epoxide
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6506876B1 (en) * 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
DE19505263A1 (de) 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
EP1136498A1 (en) 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease
PL194025B1 (pl) * 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
AU750207B2 (en) * 1997-06-13 2002-07-11 Cydex Pharmaceuticals, Inc. Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
US6133308A (en) * 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6099851A (en) * 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
EP1123412B1 (en) * 1998-10-20 2004-10-06 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
EP1477180A1 (en) 1999-10-20 2004-11-17 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
ATE338564T1 (de) * 2000-10-12 2006-09-15 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
FI2251344T4 (fi) 2001-01-25 2024-04-29 The United States Of America Represented By The Secretary Boronihappoyhdisteiden formulointi
AU2002308760B2 (en) * 2001-05-21 2006-05-11 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
AU2003219652A1 (en) * 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US20040116329A1 (en) * 2002-01-29 2004-06-17 Epstein Stephen E. Inhibition of proteasomes to prevent restenosis
WO2003086283A2 (en) * 2002-04-09 2003-10-23 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20030224469A1 (en) * 2002-06-03 2003-12-04 Buchholz Tonia J. Methods and kits for assays utilizing fluorescence polarization
AU2003249682A1 (en) * 2002-06-03 2003-12-19 Als Therapy Development Foundation Treatment of neurodegenerative diseases using proteasome modulators
AU2003256847A1 (en) 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer
US6749743B1 (en) * 2002-10-04 2004-06-15 Zabel Industries International, Ltd. Fuel diverter for a recirculating wastewater treatment system
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
PL2316431T3 (pl) 2003-04-08 2016-09-30 Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy
AU2004255564A1 (en) * 2003-06-10 2005-01-20 The J. David Gladstone Institutes Methods for treating lentivirus infections
US7012063B2 (en) * 2003-06-13 2006-03-14 Children's Medical Center Corporation Reducing axon degeneration with proteasome inhibitors
KR20070007075A (ko) 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
ES2358268T3 (es) * 2004-04-15 2011-05-09 Proteolix, Inc. Compuestos para la inhibición enzimática de proteasoma.
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
AU2005238445B2 (en) 2004-04-15 2012-05-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
ES2510840T3 (es) 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
WO2005111009A2 (en) * 2004-05-10 2005-11-24 Proteolix, Inc. Synthesis of amino acid keto-epoxides
ES2359004T3 (es) * 2004-08-06 2011-05-17 Onyx Therapeutics, Inc. Compuestos para inhibición enzimática de proteasoma.
AU2005295183A1 (en) * 2004-10-20 2006-04-27 CAOnyx Therapeutics, Inc. Labeled compounds for proteasome inhibition
ATE499109T1 (de) * 2004-12-07 2011-03-15 Proteolix Inc Zusammensetzung zur proteasomhemmung
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
PL2623113T3 (pl) 2005-11-09 2018-05-30 Onyx Therapeutics, Inc. Związek do hamowania enzymu
AR057227A1 (es) 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007122686A1 (ja) * 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
EP2484688B1 (en) * 2006-06-19 2016-06-08 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
WO2008033807A2 (en) 2006-09-13 2008-03-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer
AU2008209555A1 (en) 2007-01-23 2008-07-31 Gloucester Pharmaceuticals, Inc. Combination therapy comprising romidepsin and I.A. bortezomib
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
PT2178888E (pt) 2007-08-06 2012-10-04 Millennium Pharm Inc Inibidores do proteassoma
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8367617B2 (en) 2007-10-04 2013-02-05 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009051581A1 (en) 2007-10-16 2009-04-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
EA201500431A1 (ru) 2008-06-17 2015-11-30 Милленниум Фармасьютикалз, Инк. Соединения боронатного эфира и его фармацевтические составы
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN101928329B (zh) 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
JP6042724B2 (ja) 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
NZ602622A (en) 2010-03-31 2015-01-30 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2555621A4 (en) 2010-04-07 2014-07-02 Onyx Therapeutics Inc CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR

Also Published As

Publication number Publication date
CN101883779B (zh) 2014-08-06
US20130150290A1 (en) 2013-06-13
DOP2010000095A (es) 2010-06-30
HUE029665T2 (en) 2017-03-28
CY1117710T1 (el) 2017-05-17
HRP20160808T4 (hr) 2020-05-29
KR20170040374A (ko) 2017-04-12
US8921583B2 (en) 2014-12-30
EA024437B1 (ru) 2016-09-30
RS54847B2 (sr) 2019-09-30
IL204890A0 (en) 2010-11-30
EP2612856A2 (en) 2013-07-10
NZ598436A (en) 2014-03-28
SG185994A1 (en) 2012-12-28
DK2207791T4 (da) 2019-10-07
EP2612856A3 (en) 2014-03-26
EP2612865A3 (en) 2014-03-19
EP2612856B8 (en) 2018-10-17
TWI501773B (zh) 2015-10-01
KR20150131405A (ko) 2015-11-24
CO6270366A2 (es) 2011-04-20
KR20100088664A (ko) 2010-08-10
KR20170125413A (ko) 2017-11-14
JP2010540637A (ja) 2010-12-24
ES2578905T3 (es) 2016-08-02
TW200924789A (en) 2009-06-16
US8921324B2 (en) 2014-12-30
ME02462B (me) 2017-02-20
IL223698A0 (en) 2013-02-03
MA31831B1 (fr) 2010-11-01
EP2207791A1 (en) 2010-07-21
CL2012003441A1 (es) 2013-12-13
PH12013501377A1 (en) 2014-08-27
EP2612856B1 (en) 2018-07-18
AU2008307510A1 (en) 2009-04-09
IL238246A (en) 2016-05-31
WO2009045497A1 (en) 2009-04-09
CR11364A (es) 2010-07-09
IL238247A (en) 2016-05-31
EA201070429A1 (ru) 2010-10-29
KR20160086980A (ko) 2016-07-20
SA08290624B1 (ar) 2013-08-18
SI2207791T2 (sl) 2019-09-30
PL2207791T3 (pl) 2016-10-31
MY166950A (en) 2018-07-25
MY173938A (en) 2020-02-27
DK2207791T3 (en) 2016-07-25
ES2684340T3 (es) 2018-10-02
ECSP10010103A (es) 2010-06-29
HRP20160808T1 (hr) 2016-08-26
CA2701778A1 (en) 2009-04-09
CN101883779A (zh) 2010-11-10
US8367617B2 (en) 2013-02-05
MX2010003732A (es) 2010-08-09
ES2578905T5 (es) 2020-03-18
EP2207791B1 (en) 2016-04-13
CL2008002966A1 (es) 2010-06-25
JP5734656B2 (ja) 2015-06-17
SG10201902704TA (en) 2019-04-29
AR068681A1 (es) 2009-11-25
JP2015163619A (ja) 2015-09-10
IL238248A (en) 2016-12-29
SI2207791T1 (sl) 2016-07-29
EA018973B1 (ru) 2013-12-30
NZ584814A (en) 2012-03-30
US20130150289A1 (en) 2013-06-13
ZA201002770B (en) 2022-03-30
CA2701778C (en) 2018-09-11
PL2207791T5 (pl) 2020-07-27
US20090105156A1 (en) 2009-04-23
HK1149573A1 (en) 2011-10-07
PT2207791T (pt) 2016-07-12
EP2207791B2 (en) 2019-08-07
RS54847B1 (sr) 2016-10-31
EP2612865A2 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
EA201201476A1 (ru) Синтез кето-эпоксидов аминокислот
WO2005111009A3 (en) Synthesis of amino acid keto-epoxides
CY1113985T1 (el) Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξυαμιδο-πυριδινο βενζοϊκων οξεων
EA200900793A1 (ru) Способ получения эзетимиба и его производных
CY1110411T1 (el) Μεθοδος για την παραγωγη 3-οξο-πρεγν-4-ενο-21,17-καρβολακτονων μεσω της οξειδωσης 17-(3-υδροξυπροπυλο)-3,17-διυδροξυανδροστανιων ανευ μεταλλου
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
UA111142C2 (uk) Одержання заміщених похідних 2-фторакрилової кислоти
CL2009000503A1 (es) Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida.
DK2285765T3 (da) Fremgangsmåde til fremstilling af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
EA201892516A1 (ru) Способ и интермедиаты для 6,7-альфа-эпоксидирования стероидных 4,6-диенов
ATE489352T1 (de) Verfahren zur herstellung von brenztraubensäure
EA201200820A1 (ru) Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов
ATE518828T1 (de) Ein-topf-verfahren zur herstellung von 3-(2,2,2- trimethylhydrazinium)propionat-dihydrat
ATE466003T1 (de) Herstellung von 2-aminothiazol-5- carbonsäurederivaten
EA200702428A1 (ru) Способы получения 4-бифенилилазетидин-2-онов
EA201270343A1 (ru) Фотохимический способ получения артемисинина
WO2010059916A3 (en) Preparation of docetaxel
EA201100718A1 (ru) Способ получения г-ксф человека
ATE517890T1 (de) Verfahren zur herstellung von reinem irbesartan
IT1394296B1 (it) Metodo di sintesi dell'acido glicocolico.
WO2006105051A3 (en) Synthesis of diketopiperazines
NO20064273L (no) Fremgangsmate for semisyntese av deserpidin
MX343024B (es) Nuevo procedimiento para la produccion de 4-aminobut-2-enolidas partiendo de 4-alcoxifuran-2(5h)-ona o 4-arilalcoxifuran-2-(5h)-on a.
MX2011009734A (es) Nuevo procedimiento de preparacion de compuestos de enaminocarbonilio.
ATE546458T1 (de) Verfahren zur herstellung von 6-alpha, 9-alpha-

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM